EUVIMEDEUVIMED entdecken
Crossref

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pediatric Abdominal Rhabdomyosarcoma: Experience of a Reference Pediatric Oncosurgical Center

Cristian Urla iD, Benedikt Wagner, Andreas Schmidt iD, Frank Fideler, Jürgen Schäfer, Felix Neunhoeffer, Martin Ebinger iD, Guido Seitz, Jörg Fuchs

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Cristian Urla und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital of Tuebingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Cytoreduction Surgical Procedures, Abdominal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric abdominal rhabdomyosarcoma (RMS) represents an oncosurgical challenge. For adults with peritoneal carcinomatosis and for children/adolescents with desmoplastic small round cell tumors (DSRCT), cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to be an effective treatment. Thereby, we present the largest series on CRS and HIPEC in patients with abdominal RMS. Patients and Methods Between August 2013 and January 2024, 18 patients (9 female and 9 male) with abdominal RMS underwent CRS and HIPEC at our institution. All patients were treated according to an institutionalized protocol. The indication for surgery was established by a multidisciplinary national tumor board. HIPEC was performed using cisplatin (37.5–100 mg/m 2 ) and doxorubicin (15–30 mg/m 2 ) for 60 min at 42°C. A retrospective review of patient's records was performed.

Results

The median age at operation was 3.8 years. A complete cytoreduction was achieved in 17/18 patients. Median length of hospital stay was 11 days. Mean length of ICU stay was 2.5 days. No procedure‐associated complications and no major short‐/long‐term toxicities were recorded. The median follow‐up was 20 months. The 5‐year overall survival (OS) and event‐free survival (EFS) were 72% and 53%, respectively. Patients >10 years and those with alveolar histology had the worst prognosis (OS 0%). Patients with relapse after HIPEC (6/18) had a significantly poorer survival compared with those without recurrence (OS 33% vs. 100%, p = 0.001).

Conclusions

CRS and HIPEC are effective in patients with abdominal RMS. Patients >10 years, those with alveolar RMS and those with relapse after HIPEC had the worst outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperthermic Intraperitoneal ChemotherapyCytoreduction Surgical ProceduresAbdominal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPeritoneal NeoplasmsRhabdomyosarcomaHumansFemaleMaleChildChild, PreschoolRetrospective StudiesAdolescentCombined Modality TherapyFollow-Up StudiesDoxorubicinInfantSurvival RatePrognosisCisplatin

Stichwörter der Autor:innen

abdominalcytoreductive surgeryhyperthermic intraperitoneal chemotherapy (HIPEC)pediatricrhabdomyosarcoma

Substanzen

DoxorubicinCisplatin

Autor:innen und Institutionen

  • Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital of Tuebingen, Tübingen, Germany.
  • Department of Anesthesiology, University Hospital of Tuebingen, Tübingen, Germany.
  • Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen, Tübingen, Germany.
  • Department of Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine, University Children's Hospital of Tuebingen, Tübingen, Germany.
  • Department of Pediatric Hematology and Oncology, University Children's Hospital of Tuebingen, Tübingen, Germany.
  • Department of Pediatric Surgery and Urology, University Hospital Giessen/Marburg, Marburg, Germany.

ORCID-Profile: Cristian Urla, Andreas Schmidt, Martin Ebinger

Zitieren

APA

Urla, C., Wagner, B., Schmidt, A., Fideler, F., Schäfer, J., Neunhoeffer, F., Ebinger, M., Seitz, G., & Fuchs, J. (2025). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pediatric Abdominal Rhabdomyosarcoma: Experience of a Reference Pediatric Oncosurgical Center. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31573

Vancouver

Urla C, Wagner B, Schmidt A, Fideler F, Schäfer J, Neunhoeffer F, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pediatric Abdominal Rhabdomyosarcoma: Experience of a Reference Pediatric Oncosurgical Center. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31573

BibTeX
@article{Urla2025,
  author = {Urla, Cristian and Wagner, Benedikt and Schmidt, Andreas and Fideler, Frank and Schäfer, Jürgen and Neunhoeffer, Felix and Ebinger, Martin and Seitz, Guido and Fuchs, Jörg},
  title = {Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pediatric Abdominal Rhabdomyosarcoma: Experience of a Reference Pediatric Oncosurgical Center},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31573}
}
Kostenlos starten →